133 related articles for article (PubMed ID: 34171282)
1. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia.
Andrés-Jensen L; Attarbaschi A; Bardi E; Barzilai-Birenboim S; Bhojwani D; Hagleitner MM; Halsey C; Harila-Saari A; van Litsenburg RRL; Hudson MM; Jeha S; Kato M; Kremer L; Mlynarski W; Möricke A; Pieters R; Piette C; Raetz E; Ronceray L; Toro C; Grazia Valsecchi M; Vrooman LM; Weinreb S; Winick N; Schmiegelow K;
Lancet Haematol; 2021 Jul; 8(7):e513-e523. PubMed ID: 34171282
[TBL] [Abstract][Full Text] [Related]
2. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Schmiegelow K; Attarbaschi A; Barzilai S; Escherich G; Frandsen TL; Halsey C; Hough R; Jeha S; Kato M; Liang DC; Mikkelsen TS; Möricke A; Niinimäki R; Piette C; Putti MC; Raetz E; Silverman LB; Skinner R; Tuckuviene R; van der Sluis I; Zapotocka E;
Lancet Oncol; 2016 Jun; 17(6):e231-e239. PubMed ID: 27299279
[TBL] [Abstract][Full Text] [Related]
3. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
5. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study.
Mulrooney DA; Hyun G; Ness KK; Bhakta N; Pui CH; Ehrhardt MJ; Krull KR; Crom DB; Chemaitilly W; Srivastava DK; Relling MV; Jeha S; Green DM; Yasui Y; Robison LL; Hudson MM
Lancet Haematol; 2019 Jun; 6(6):e306-e316. PubMed ID: 31078468
[TBL] [Abstract][Full Text] [Related]
6. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
8. Minimising the long-term adverse effects of childhood leukaemia therapy.
Langebrake C; Reinhardt D; Ritter J
Drug Saf; 2002; 25(15):1057-77. PubMed ID: 12452732
[TBL] [Abstract][Full Text] [Related]
9. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-related toxicities follow a typical pattern in children treated for acute lymphoblastic leukaemia.
Rokkanen R; Aarnivala H; Pokka T; Niinimäki R
Acta Paediatr; 2024 May; 113(5):1103-1111. PubMed ID: 38178211
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
13. Physician-defined severe toxicities occurring during and after cancer treatment: Modified consensus definitions and clinical applicability in the evaluation of cancer treatment.
Nielsen CG; Thomsen BL; Als-Nielsen B; Conyers R; Jeha S; Mateos MK; Mlynarski W; Pieters R; Rathe M; Schmiegelow K; Andrés-Jensen L
Front Pediatr; 2023; 11():1155449. PubMed ID: 37181427
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
15. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.
Cheung YT; Sabin ND; Reddick WE; Bhojwani D; Liu W; Brinkman TM; Glass JO; Hwang SN; Srivastava D; Pui CH; Robison LL; Hudson MM; Krull KR
Lancet Haematol; 2016 Oct; 3(10):e456-e466. PubMed ID: 27658980
[TBL] [Abstract][Full Text] [Related]
16. Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003.
Bartram J; Wade R; Vora A; Hancock J; Mitchell C; Kinsey S; Steward C; Moppett J; Goulden N
Arch Dis Child; 2016 May; 101(5):449-54. PubMed ID: 26865705
[TBL] [Abstract][Full Text] [Related]
17. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.
Wolthers BO; Frandsen TL; Baruchel A; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Grell K; Inaba H; Kovacs G; Liang DC; Mateos M; Mondelaers V; Möricke A; Ociepa T; Samarasinghe S; Silverman LB; van der Sluis IM; Stanulla M; Vrooman LM; Yano M; Zapotocka E; Schmiegelow K;
Lancet Oncol; 2017 Sep; 18(9):1238-1248. PubMed ID: 28736188
[TBL] [Abstract][Full Text] [Related]
18. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related toxicities in children with acute lymphoblastic leukaemia predisposition syndromes.
Schmiegelow K
Eur J Med Genet; 2016 Dec; 59(12):654-660. PubMed ID: 26876989
[TBL] [Abstract][Full Text] [Related]
20. Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL97 study.
Li CK; Chik KW; Ha SY; Lee AC; Yuen HL; Ling SC; Lee V; Chan GC; Shing MM; Chan LC; Ng MH
Hong Kong Med J; 2006 Feb; 12(1):33-9. PubMed ID: 16495587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
